Related Experiment Video
Updated: Dec 26, 2025

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
Decoding molecular interplay between RUNX1 and FOXO3a underlying the pulsatile IGF1R expression during acquirement of
Ajit C Dhadve1, Kishore Hari2, Bharat Rekhi3
1Imaging Cell Signaling & Therapeutics Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Kharghar, Navi Mumbai, India; Homi Bhabha National Institute, Anushakti Nagar, Mumbai, India.
Abstract:
Hyperactive Insulin like growth factor-1-receptor (IGF1R) signalling is associated with development of therapy resistance in many cancers. We recently reported a pulsatile nature of IGF1R during acquirement of platinum-taxol resistance in Epithelial Ovarian Cancer (EOC) cells and a therapy induced upregulation in IGF1R expression in tumors of a small cohort of high grade serous EOC patients. Here, we report Runt-related transcription factor 1 (RUNX1) as a novel transcriptional regulator which along with another known regulator Forkhead Box O3 (FOXO3a), drives the dynamic modulation of IGF1R expression during platinum-taxol resistance development in EOC cells. RUNX1-FOXO3a cooperatively bind to IGF1R promoter and produce a transcriptional surge during onset of resistance and such co-operativity falls apart when cells attain maximal resistance resulting in decreased IGF1R expression. The intriguing descending trend in IGF1R and FOXO3a expressions is caused by a Protein Kinase B (AKT)-FOXO3a negative feedback loop exclusively present in the highly resistant cells eliciting the pulsatile behaviour of IGF1R and FOXO3a. In vivo molecular imaging revealed that RUNX1 inhibition causes significant attenuation of the IGF1R promoter activity, decreased tumorigenicity and enhanced drug sensitivity of tumors of early resistant cells. Altogether our findings delineate a dynamic interplay between several molecular regulators driving pulsatile IGF1R expression and identify a new avenue for targeting EOC through RUNX1-IGF1R axis during acquirement of chemoresistance.
Insights
Runt-related transcription factor 1 (RUNX1) and Forkhead Box O3 (FOXO3a) regulate Insulin-like growth factor 1 receptor (IGF1R) expression during ovarian cancer chemoresistance. RUNX1 inhibition reduces tumor growth and enhances drug sensitivity.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Hyperactive Insulin-like Growth Factor-1 Receptor (IGF1R) signaling is linked to cancer therapy resistance.
- Epithelial Ovarian Cancer (EOC) cells exhibit pulsatile IGF1R expression during platinum-taxol resistance acquisition.
- Therapy can induce IGF1R upregulation in high-grade serous EOC patient tumors.
Purpose of the Study:
- To identify novel transcriptional regulators of IGF1R during chemoresistance development in EOC.
- To elucidate the cooperative and dynamic roles of RUNX1 and FOXO3a in modulating IGF1R expression.
- To investigate the therapeutic potential of targeting the RUNX1-IGF1R axis in chemoresistant EOC.
Main Methods:
- Investigated the roles of RUNX1 and FOXO3a in regulating IGF1R expression in EOC cells.
- Analyzed the cooperative binding of RUNX1-FOXO3a to the IGF1R promoter.
- Examined the influence of a Protein Kinase B (AKT)-FOXO3a negative feedback loop on IGF1R and FOXO3a expression.
- Utilized in vivo molecular imaging to assess the effects of RUNX1 inhibition on tumor growth and drug sensitivity.
Main Results:
- RUNX1 and FOXO3a cooperatively bind to the IGF1R promoter, driving an initial surge in IGF1R expression during resistance development.
- This cooperation diminishes in highly resistant cells, leading to decreased IGF1R expression.
- A negative feedback loop involving AKT and FOXO3a in resistant cells causes pulsatile IGF1R and FOXO3a expression.
- RUNX1 inhibition in early resistant cells significantly reduced IGF1R promoter activity, tumorigenicity, and enhanced drug sensitivity.
Conclusions:
- RUNX1 acts as a novel transcriptional regulator of IGF1R in EOC chemoresistance.
- A dynamic interplay between RUNX1, FOXO3a, and AKT governs pulsatile IGF1R expression.
- Targeting the RUNX1-IGF1R axis presents a promising therapeutic strategy for overcoming chemoresistance in EOC.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Master Transcription Regulators
Regulation of Expression at Multiple Steps
Regulation of Expression Occurs at Multiple Steps
Regulation of Expression Occurs at Multiple Steps
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...

